TKIs (EGFR VEGF BTK etc.)

Delve into the world of TKIs (EGFR VEGF BTK etc.) in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and insights on TKIs (EGFR VEGF BTK etc.) to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

AstraZeneca Submits FDA NDA for Orpathys–Tagrisso Combination – Targeting MET‑Altered NSCLC After EGFR TKI Failure
CompanyDrug

AstraZeneca Submits FDA NDA for Orpathys–Tagrisso Combination – Targeting MET‑Altered NSCLC After EGFR TKI Failure

HutchMed (China) Limited (NASDAQ: HCM; HKG: 0013) announced that its partner AstraZeneca plc (NYSE: AZN) has submitted a New Drug Application (NDA) to the U.S. FDA for the combination therapy…

Ascletis Reports Positive 28‑Day Proof‑of‑Concept Results for ASC50 – Oral IL‑17A Small Molecule Delivers 48.9% Placebo‑Adjusted PASI Reduction in Mild‑to‑Moderate Plaque Psoriasis

Ascletis Reports Positive 28‑Day Proof‑of‑Concept Results for ASC50 – Oral IL‑17A Small Molecule Delivers 48.9% Placebo‑Adjusted PASI Reduction in Mild‑to‑Moderate Plaque Psoriasis

CSPC's SYS6077 Wins NMPA Clinical Trial Approval – Off‑the‑Shelf Universal mRNA Cancer Vaccine for Advanced Malignant Tumors

CSPC’s SYS6077 Wins NMPA Clinical Trial Approval – Off‑the‑Shelf Universal mRNA Cancer Vaccine for Advanced Malignant Tumors

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Qilu Pharmaceutical’s Iruplinalkib Gains Additional Indication Approval in China for ALK-Positive NSCLC

CompanyDrug

Allist Pharmaceuticals’ Furmonertinib and AstraZeneca’s Enhertu Earn Breakthrough Designations in China for NSCLC Treatments

CompanyDrug

CSBIO’s Multi-Kinase Inhibitor CSCJC3456 Gets Green Light for Clinical Trials in Advanced Solid Tumors

CompanyDeals

Beijing Avistone Pharmaceuticals Raises RMB 1 Billion in Series B Funding to Accelerate Drug Development

CompanyDrug

Konruns Pharmaceutical Receives NMPA Go-Ahead for KC1036 Esophageal Cancer Study

Company

CStone Pharmaceuticals Disbands Sales Team for Gavreto After NRDL Setback

CompanyDrug

Sino Biopharmaceutical Completes Enrollment for Phase III Trial of Anlotinib in Soft Tissue Sarcoma

CompanyDrug

Konruns Pharmaceutical Gets NMPA Approval for KC1036 Clinical Study in Juventus sarcoma

Show More